Letter: infliximab vs. adalimumab in treating ambulatory perianal fistulising Crohn's disease

被引：2
|
作者：
Tursi, A. [1 ]
Elisei, W. [2 ]
Picchio, M. [3 ]
Zampaletta, C. [4 ]
Faggiani, R. [4 ]
Brandimarte, G. [5 ]
机构：
[1] ASL BAI, Gastroenterol Serv, Andria, BI, Italy
[2] ASL RMH, Div Gastroenterol, Rome, Italy
[3] ASL RMH, P Colombo Hosp, Div Surg, Rome, Italy
[4] Belcolle Hosp, Div Gastroenterol, Viterbo, Italy
[5] Cristo Re Hosp, Div Gastroenterol, Rome, Italy
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2014年 / 40卷 / 02期
关键词：
ACTIVITY INDEX;
D O I：
10.1111/apt.12828
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
下载
收藏
页码：218 / 220
页数：3
相关论文
共 50 条
  • [1] Infliximab vs. Adalimumab for Crohn's disease
    Mulani, P.
    Chao, J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (10) : 1265 - 1266
  • [2] HIGHER INFLIXIMAB AND ADALIMUMAB TROUGH LEVELS ARE NOT ASSOCIATED WITH FISTULA HEALING IN PATIENTS WITH FISTULISING PERIANAL CROHN'S DISEASE
    Gilbert, Lauren E.
    Cheung, Wa
    Gerstenmaier, Jan F.
    Martin, Catherine A.
    Sparrow, Miles
    GASTROENTEROLOGY, 2019, 156 (06) : S112 - S112
  • [3] Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease
    Gu, Bonita
    Venkatesh, Kavya
    Williams, Astrid-Jane
    Ng, Watson
    Corte, Crispin
    Gholamrezaei, Ali
    Ghaly, Simon
    Xuan, Wei
    Paramsothy, Sudarshan
    Connor, Susan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (23) : 2597 - 2608
  • [4] Infliximab vs. Adalimumab for Crohn's disease: authors' reply
    Kaplan, G. G.
    Hur, C.
    Korzenik, J.
    Sands, B. E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (10) : 1266 - 1267
  • [5] Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease
    Bonita Gu
    Kavya Venkatesh
    Astrid-Jane Williams
    Watson Ng
    Crispin Corte
    Ali Gholamrezaei
    Simon Ghaly
    Wei Xuan
    Sudarshan Paramsothy
    Susan Connor
    World Journal of Gastroenterology, 2022, (23) : 2597 - 2608
  • [6] HIGHER INFLIXIMAB AND ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH FISTULA HEALING IN PATIENTS WITH FISTULISING PERIANAL CROHN'S DISEASE
    Gu, Bonita
    Venkatesh, Kavya
    Williams, Astrid-Jane
    Ng, Watson
    Corte, Crispin
    Simon, Ghaly
    Xuan, Wei
    Paramsothy, Sudarshan
    Connor, Susan J.
    GASTROENTEROLOGY, 2020, 158 (06) : S467 - S468
  • [7] Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease
    Gu, B.
    Venkatesh, K.
    Williams, A. J.
    Ng, W.
    Corte, C.
    Ghaly, S.
    Xuan, W.
    Paramsothy, S.
    Connor, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S490 - S491
  • [8] INFLIXIMAB VERSUS ADALIMUMAB IN THE TREATMENT OF PERIANAL CROHN'S DISEASE
    Maas, Laura A.
    Limketkai, Berkeley N.
    Lazarev, Mark
    Melia, Joanna
    Selaru, Florin M.
    Parian, Alyssa M.
    GASTROENTEROLOGY, 2022, 162 (07) : S817 - S817
  • [9] Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?
    Srinivas, N. R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (07) : 771 - 772
  • [10] Infliximab vs Adalimumab for Crohn's Disease Reply
    Osterman, Mark T.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (01) : 210 - 211
12345